DexCom, Abbott Agree to Settlement in Patent Litigation

By Connor Hart

  DexCom and Abbott Diabetes Care entered a settlement and patent cross-license settlement, resolving all excellent litigation between the businesses. 

  The businesses have been concerned in world patent litigation, with each having accused the opposite of infringing sure patents, and every has filed counterclaims and actions to invalidate the opposite get together's patents, DexCom stated in a Securities and Alternate Fee submitting Monday. 

  On Friday, the businesses entered a settlement, beneath which each granted the opposite "a worldwide, royalty-free, non-exclusive, totally paid-up license to sure patents and patent functions referring to analyte sensing." This license extends to all of the patents asserted within the litigation, DexCom stated. 

  Additionally beneath the phrases of the settlement, which doesn't obligate both firm to pay royalties or some other type of monetary compensation, each events agreed to not sue till Dec. 20, 2034, and won't problem the patents and patent functions licensed beneath the settlement, based on DexCom. 

  Write to Connor Hart at [email protected] 

  (END) Dow Jones Newswires

  December 23, 2024 16:57 ET (21:57 GMT)
Copyright (c) 2024 Dow Jones & Firm, Inc.